People · Operator
Named in public records as an officer, director or promoter · active 2011–2015 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Lycera Corp | — | Pharmaceuticals | Series B | $85.7M | $1.0B | 2015 |
| Variation Biotechnologies (US), Inc. | — | Biotechnology | Series A | $17.1M | $54.2M | 2011 |
| Macrogenics Inc | — | Biotechnology | Series A | $12.0M | $434.4M | 2011 |
| Allozyne Inc | — | Biotechnology | Seed | $8.2M | $108.9M | 2012 |
Michael Steinmetz at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael Steinmetz on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Steven Gillis | 3 | 23 |
| PAUL SEKHRI | 2 | 7 |
| Jeffrey Leiden | 2 | 4 |
| Kristina Burow | 1 | 16 |
| Steve Gillis | 1 | 13 |
| Nina Kjellson | 1 | 11 |
| Arnold Oronsky | 1 | 10 |
| Ed Hurwitz | 1 | 9 |
| SCOTT ROCKLAGE | 1 | 9 |
| Carl Weissman | 1 | 8 |
| Timothy M. Mayleben | 1 | 4 |
| Kathleen M. Metters | 1 | 4 |
| Tim Mayleben | 1 | 4 |
| Michael Hayden | 1 | 4 |
| Jeff Baxter | 1 | 4 |
| Egidio Nascimento | 1 | 3 |
| Gary D. Glick | 1 | 3 |
| David E. Anderson | 1 | 3 |
| Kevin Forrest | 1 | 3 |
| TIMOTHY MAYLEBEN | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.